Furthermore, ruxolitinib inhibits the development of PH and partially reduced right ventricular hypertrophy in two independent animal models of PAH (a monocrotaline rat model and chronic hypoxia mouse model) through the blockade of the JAK2–STAT3 signaling pathway [116]. Here, STAT3 is linked to pulmonary arterial hypertension.